The FDA rejected the new drug application for a Levo Therapeutics treatment for the rare metabolic disorder Prader-Willi syndrome. According to Levo, the agency said the data submitted were insufficient to support approval and the regulator wants the company to run another clinical trial.
The team behind the World Without Disease Accelerator, part of Janssen Research & Development, one of the Janssen Pharmaceutical companies of Johnson & Johnson, is embracing an ambitious paradigm focused on disease prevention, interception and cure.
In this episode hear how improving benefit verification, prior authorizations, and patient affordability with smart integrations and real-time eligibility can streamline healthcare workflows.
Genetic testing can play a critical role in helping potential parents understand their options if they are carriers for a wide array of genetic disorders, such as cystic fibrosis.
A Dallas biotech startup has raised money to begin clinical trials for what it hopes could be a treatment for the top genetic cause of infant mortality. AveXis is developing a viral gene therapy for infants with spinal muscular atrophy. With a new round of funding led by PBM Capital, the company is hoping to […]